923009-50-1

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 1-oxo-2,7-diazaspiro[4.5]decane-7-carboxylate is used as a building block in organic synthesis for its versatile functional groups that can be further modified or utilized in the construction of more complex molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-butyl 1-oxo-2,7-diazaspiro[4.5]decane-7-carboxylate is used as a starting material or intermediate in the development of new drugs. Its unique structure and functional groups may offer novel biological activities, making it a promising candidate for drug discovery and design.
Used in Drug Discovery:
Tert-butyl 1-oxo-2,7-diazaspiro[4.5]decane-7-carboxylate is employed as a scaffold in drug discovery for its potential to be optimized and modified to target specific biological pathways or receptors, leading to the development of innovative therapeutic agents.
Used in Chemical Research:
In the field of chemical research, tert-butyl 1-oxo-2,7-diazaspiro[4.5]decane-7-carboxylate is used as a subject of study to explore its reactivity, stability, and interactions with other molecules, contributing to the understanding of complex chemical systems and the development of new synthetic strategies.

InChI:InChI=1/C15H26N2O3/c1-5-16-10-8-15(12(16)18)7-6-9-17(11-15)13(19)20-14(2,3)4/h5-11H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1187173-43-8 2,7-diazaspiro[4.5]decan-1-one hydrochloride 
• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 

Downstream Products

• 923009-51-2 C₁₅H₂₆N₂O₃ 

Relevant academic research and scientific papers

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly2162 and Glu2230, we used ligand- and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety